The Microbiome and Immuno-oncology

February 5, 2019

With a growing body of pre-clinical and clinical research, the influence of bacteria on human health and disease has emerged from the shadows and into the limelight.

Spotlight

Caris Life Sciences

Caris Life Sciences™ was founded because of an idea — that personalized and precise information can improve healthcare for everyone. This idea drives everything we do at Caris Life Sciences.Caris combines the rigor of an academic medical institution with the innovative spirit of a technology company. We believe that innovative, high-quality testing and information can lead to more effective treatment selection and ultimately to better outcomes for patients with cancer and other complex diseases.

OTHER WHITEPAPERS
news image

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Read More
news image

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Read More
news image

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Read More
news image

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Read More
news image

A New Generation of Cancer Immunotherapies

whitePaper | June 9, 2022

Despite recent progress in fighting cancer the sad reality is that it remains a leading cause of morbidity and mortality. Some of the most promising new treatments have emerged from the convergence of the oncology and immunology fields.

Read More
news image

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Read More

Spotlight

Caris Life Sciences

Caris Life Sciences™ was founded because of an idea — that personalized and precise information can improve healthcare for everyone. This idea drives everything we do at Caris Life Sciences.Caris combines the rigor of an academic medical institution with the innovative spirit of a technology company. We believe that innovative, high-quality testing and information can lead to more effective treatment selection and ultimately to better outcomes for patients with cancer and other complex diseases.

Events